Article

Tislelizumab plus lenvatinib as the first-line therapy in patients with advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, single-centre, phase 2 trial and metabolic biomarker analysis

2026-02-13

Abstract excerpt

<title>Abstract</title> <p> Background Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare subtype of kidney malignancy with poor prognosis. Standard of care for advanced FH-RCC has not been established, although our prior retrospective study showed encouraging antitumor activity of immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combinations. Objective We aimed to condu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cddfa0e4-ba88-5882-8a25-e8f0afee4a6d
DOI: 10.21203/rs.3.rs-8771803/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tislelizumab plus lenvatinib as the first-line therapy in patients with advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, single-centre, phase 2 trial and metabolic biomarker analysisDOI 10.21203/rs.3.rs-8771803/v1Read

Fumarate hydratase-deficient renal cell carcinoma: a single institution-based study of 29 patients by clinicopathological, immunohistochemical and genetic approachesSemantic proximity Read

Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaSemantic proximity Read

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.Semantic proximity Read

Genomic and Metabolic Hallmarks of SDH- and FH-Deficient Renal Cell CarcinomasSemantic proximity Read

Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.Semantic proximity Read

Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinomaSemantic proximity Read

Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.Semantic proximity Read

Fumarate hydratase as a therapeutic target in renal cancerSemantic proximity Read

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell CarcinomasSemantic proximity Read

FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancerSemantic proximity Read

AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell CarcinomaSemantic proximity Read

Probing intratumoral metabolic compartmentalisation in fumarate hydratase-deficient renal cancer using clinical hyperpolarised<sup>13</sup>C-MRI and mass spectrometry imagingSemantic proximity Read